share_log

Goldman Sachs Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $8

Benzinga ·  Jan 9 10:03

Goldman Sachs analyst Chris Shibutani downgrades Revance Therapeutics (NASDAQ:RVNC) from Buy to Neutral and lowers the price target from $30 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment